{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:52:30Z","timestamp":1789498350158,"version":"build-2803163510"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1038\/s41409-025-02582-6","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T12:46:31Z","timestamp":1744893991000},"page":"940-947","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["CAR-T for multiple myeloma: practice pearls"],"prefix":"10.1038","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4529-4853","authenticated-orcid":false,"given":"Daniel","family":"O\u2019Leary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9325-432X","authenticated-orcid":false,"given":"Veronika","family":"Bachanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"2582_CR1","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","volume":"31","author":"M Sheykhhasan","year":"2024","unstructured":"Sheykhhasan M, Ahmadieh-Yazdi A, Vicidomini R, Poondla N, Tanzadehpanah H, Dirbaziyan A, et al. CAR T therapies in multiple myeloma: unleashing the future. Cancer Gene Ther. 2024;31:667\u201386.","journal-title":"Cancer Gene Ther"},{"key":"2582_CR2","unstructured":"National Comprehenisve Cancer Network. NCCN Guidelines: Multiple Myeloma, Version 4.2024. 2024 [cited 2024 Jul 13]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf"},{"key":"2582_CR3","unstructured":"Research C for DE and. FDA approves idecabtagene vicleucel for multiple myeloma. FDA. 2021 Jun 11 [cited 2024 Jul 13]; Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-idecabtagene-vicleucel-multiple-myeloma"},{"key":"2582_CR4","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene Vicleucel in relapsed and Refractory multiple Myeloma. N. Engl J Med. 2021;384:705\u201316.","journal-title":"N. Engl J Med"},{"key":"2582_CR5","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398:314\u201324.","journal-title":"Lancet"},{"key":"2582_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-022-00629-1","volume":"12","author":"AD Cohen","year":"2022","unstructured":"Cohen AD, Parekh S, Santomasso BD, G\u00e1llego P\u00e9rez-Larraya J, van de Donk NWCJ, Arnulf B, et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022;12:1\u20139.","journal-title":"Blood Cancer J"},{"key":"2582_CR7","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/j.clml.2024.01.014","volume":"24","author":"S Ailawadhi","year":"2024","unstructured":"Ailawadhi S, Shune L, Wong SW, Lin Y, Patel K, Jagannath S. Optimizing the CAR T-cell therapy experience in multiple myeloma: clinical pearls from an expert roundtable. Clin Lymphoma, Myeloma Leuk. 2024;24:e217\u201325.","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"key":"2582_CR8","doi-asserted-by":"publisher","first-page":"10402","DOI":"10.1182\/blood-2022-167804","volume":"140","author":"R Villanueva","year":"2022","unstructured":"Villanueva R, Hansen DK, Tonseth RP, Gage KL, Wei Z, De Avila G, et al. High metabolic tumor volume is associated with higher toxicity and decreased efficacy of BCMA CAR-T cell therapy in multiple myeloma. Blood. 2022;140:10402\u20134.","journal-title":"Blood"},{"key":"2582_CR9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1182\/bloodadvances.2023011992","volume":"8","author":"C Baguet","year":"2024","unstructured":"Baguet C, Larghero J, Mebarki M. Early predictive factors of failure in autologous CAR T-cell manufacturing and\/or efficacy in hematologic malignancies. Blood Adv. 2024;8:337\u201342.","journal-title":"Blood Adv"},{"key":"2582_CR10","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/bjh.18831","volume":"202","author":"T Jo","year":"2023","unstructured":"Jo T, Yoshihara S, Okuyama Y, Fujii K, Henzan T, Kahata K, et al. Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan. Br J Haematol. 2023;202:256\u201366.","journal-title":"Br J Haematol"},{"key":"2582_CR11","unstructured":"Cancer Network [Internet]. 2024 [cited 2024 Jul 13]. FDA Approves Ide-Cel in Previously Treated Multiple Myeloma. Available from: https:\/\/www.cancernetwork.com\/view\/fda-approves-ide-cel-in-previously-treated-multiple-myeloma"},{"key":"2582_CR12","unstructured":"Research C for BE and. CARVYKTI. FDA [Internet]. 2024 Jun 13 [cited 2024 Jul 14]; Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/carvykti"},{"key":"2582_CR13","unstructured":"Package Insert: ABECMA [Internet]. [cited 2024 Jul 13]. Available from: https:\/\/www.fda.gov\/media\/147055\/download?attachment"},{"key":"2582_CR14","unstructured":"Package Insert: CARVYKTI [Internet]. [cited 2024 Jul 13]. Available from: https:\/\/www.fda.gov\/media\/156560\/download"},{"key":"2582_CR15","first-page":"17","volume":"30","author":"LD Anderson","year":"2024","unstructured":"Anderson LD, Dhakal B, Jain T, Oluwole OO, Shah GL, Sidana S, et al. Chimeric Antigen Receptor T cell therapy for myeloma: where are we now and what is needed to move chimeric antigen receptor T cells forward to earlier lines of therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther, Off Publ Am Soc Transplant Cell Ther. 2024;30:17\u201337.","journal-title":"Transplant Cell Ther, Off Publ Am Soc Transplant Cell Ther"},{"key":"2582_CR16","doi-asserted-by":"crossref","unstructured":"Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B From bench to bedside: the history and progress of CAR T cell therapy. Front Immunol. 2023 May 15 [cited 2024 Jul 14];14. Available from: https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/10.3389\/fimmu.2023.1188049\/full","DOI":"10.3389\/fimmu.2023.1188049"},{"key":"2582_CR17","first-page":"2430","volume":"141","author":"MD Jain","year":"2023","unstructured":"Jain MD, Smith M, Shah NN. How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood. 2023;141:2430\u201342.","journal-title":"Blood"},{"key":"2582_CR18","first-page":"2460","volume":"141","author":"T Jain","year":"2023","unstructured":"Jain T, Olson TS, Locke FL. How I treat cytopenias after CAR T-cell therapy. Blood. 2023;141:2460\u20139.","journal-title":"Blood"},{"key":"2582_CR19","first-page":"2452","volume":"141","author":"C Gutierrez","year":"2023","unstructured":"Gutierrez C, Neilan TG, Grover NS. How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy. Blood. 2023;141:2452\u20139.","journal-title":"Blood"},{"key":"2582_CR20","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s11899-021-00635-3","volume":"16","author":"PR Geethakumari","year":"2021","unstructured":"Geethakumari PR, Ramasamy DP, Dholaria B, Berdeja J, Kansagra A. Balancing quality, cost, and access during delivery of newer cellular and immunotherapy treatments. Curr Hematol Malig Rep. 2021;16:345\u201356.","journal-title":"Curr Hematol Malig Rep"},{"key":"2582_CR21","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1200\/JCO.22.01365","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, et al. Idecabtagene Vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T Consortium. J Clin Oncol. 2023;41:2087\u201397.","journal-title":"J Clin Oncol"},{"key":"2582_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2024025945","volume":"145","author":"S Sidana","year":"2025","unstructured":"Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, et al. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma. Blood. 2025;145:85\u201397.","journal-title":"Blood"},{"key":"2582_CR23","first-page":"2443","volume":"141","author":"BD Santomasso","year":"2023","unstructured":"Santomasso BD, Gust J, Perna F. How I treat unique and difficult-to-manage cases of CAR T-cell therapy\u2013associated neurotoxicity. Blood. 2023;141:2443\u201351.","journal-title":"Blood"},{"key":"2582_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/jha2.335","volume":"3","author":"ST Bhaskar","year":"2021","unstructured":"Bhaskar ST, Dholaria BR, Sengsayadeth SM, Savani BN, Oluwole OO. Role of bridging therapy during chimeric antigen receptor T cell therapy. EJHaem. 2021;3:39\u201345.","journal-title":"EJHaem"},{"key":"2582_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101095","volume":"60","author":"Y St Martin","year":"2023","unstructured":"St Martin Y, Franz JK, Agha ME, Lazarus HM. Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need. Blood Rev. 2023;60:101095.","journal-title":"Blood Rev"},{"key":"2582_CR26","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","volume":"4","author":"BL Levine","year":"2017","unstructured":"Levine BL, Miskin J, Wonnacott K, Keir C. Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev. 2017;4:92\u2013101.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2582_CR27","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20230903","volume":"221","author":"M Ayala Ceja","year":"2024","unstructured":"Ayala Ceja M, Khericha M, Harris CM, Puig-Saus C, Chen YY. CAR-T cell manufacturing: Major process parameters and next-generation strategies. J Exp Med. 2024;221:e20230903.","journal-title":"J Exp Med"},{"key":"2582_CR28","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41409-022-01905-1","volume":"58","author":"S Al Hadidi","year":"2023","unstructured":"Al Hadidi S, Szabo A, Esselmann J, Hammons L, Hussain M, Ogunsesan Y, et al. Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy. Bone Marrow Transpl. 2023;58:443\u20135.","journal-title":"Bone Marrow Transpl"},{"key":"2582_CR29","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jtct.2023.01.012","volume":"29","author":"T Kourelis","year":"2023","unstructured":"Kourelis T, Bansal R, Berdeja J, Siegel D, Patel K, Mailankody S, et al. Ethical challenges with multiple myeloma BCMA chimeric antigen receptor T cell slot allocation: a multi-institution experience. Transpl Cell Ther. 2023;29:255\u20138.","journal-title":"Transpl Cell Ther"},{"key":"2582_CR30","doi-asserted-by":"publisher","first-page":"6918","DOI":"10.1182\/blood-2023-186163","volume":"142","author":"B Bowden","year":"2023","unstructured":"Bowden B, Ciccone D, Salmon J, Alegria V, Kallenbach L, De Braganca KC. Using real-world remanufacturing and recollection data to optimize time-to-treatment in patients with out-of-specification Ciltacabtagene Autoleucel. Blood. 2023;142:6918.","journal-title":"Blood"},{"key":"2582_CR31","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1182\/hematology.2023000434","volume":"2023","author":"RS Firestone","year":"2023","unstructured":"Firestone RS, Mailankody S. Current use of CAR T cells to treat multiple myeloma. Hematology. 2023;2023:340\u20137.","journal-title":"Hematology"},{"key":"2582_CR32","doi-asserted-by":"crossref","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388:1002\u201314.","DOI":"10.1056\/NEJMoa2213614"},{"key":"2582_CR33","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","volume":"25","author":"P Rodriguez-Otero","year":"2024","unstructured":"Rodriguez-Otero P, Usmani S, Cohen AD, van de Donk NWCJ, Leleu X, G\u00e1llego P\u00e9rez-Larraya J, et al. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol. 2024;25:e205\u201316.","journal-title":"Lancet Oncol"},{"key":"2582_CR34","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1182\/blood-2024-202017","volume":"144","author":"B Dhakal","year":"2024","unstructured":"Dhakal B, Akhtar OS, Cowan AJ, Richard S, Friend R, Rees MJ, et al. Talquetamab bridging: Paving the Way to B-cell maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed\/Refractory Multiple Myeloma (RRMM). Blood. 2024;144:931.","journal-title":"Blood"},{"key":"2582_CR35","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1182\/bloodadvances.2022009019","volume":"7","author":"C Roddie","year":"2023","unstructured":"Roddie C, Neill L, Osborne W, Iyengar S, Tholouli E, Irvine D, et al. Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma. Blood Adv. 2023;7:2872\u201383.","journal-title":"Blood Adv"},{"key":"2582_CR36","doi-asserted-by":"publisher","first-page":"72.e1","DOI":"10.1016\/j.jtct.2021.11.014","volume":"28","author":"S Shahid","year":"2022","unstructured":"Shahid S, Ramaswamy K, Flynn J, Mauguen A, Perica K, Park JH, et al. Impact of bridging chemotherapy on clinical outcomes of CD19-Specific CAR T cell therapy in children\/young adults with relapsed\/refractory B cell acute lymphoblastic leukemia. Transpl Cell Ther. 2022;28:72.e1\u201372.e8.","journal-title":"Transpl Cell Ther"},{"key":"2582_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01048-0","volume":"14","author":"BA Costa","year":"2024","unstructured":"Costa BA, Flynn J, Nishimura N, Devlin SM, Farzana T, Rajeeve S, et al. Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma. Blood Cancer J. 2024;14:84.","journal-title":"Blood Cancer J"},{"key":"2582_CR38","doi-asserted-by":"publisher","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","volume":"29","author":"MR Hines","year":"2023","unstructured":"Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, et al. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. Transplant Cell Ther. 2023;29:438.e1\u2013438.e16.","journal-title":"Transplant Cell Ther"},{"key":"2582_CR39","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1177\/0885066617711386","volume":"34","author":"P Wohlfarth","year":"2019","unstructured":"Wohlfarth P, Agis H, Gualdoni GA, Weber J, Staudinger T, Schellongowski P, et al. Interleukin 1 Receptor Antagonist Anakinra, Intravenous Immunoglobulin, and Corticosteroids in the Management of Critically Ill Adult Patients With Hemophagocytic Lymphohistiocytosis. J Intensive Care Med. 2019;34:723\u201331.","journal-title":"J Intensive Care Med"},{"key":"2582_CR40","doi-asserted-by":"publisher","first-page":"e210","DOI":"10.3324\/haematol.2019.222471","volume":"105","author":"J Wang","year":"2020","unstructured":"Wang J, Wang Y, Wu L, Wang X, Jin Z, Gao Z, et al. Ruxolitinib for refractory\/relapsed hemophagocytic lymphohistiocytosis. Haematologica. 2020;105:e210\u20132.","journal-title":"Haematologica"},{"key":"2582_CR41","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjh.17331","volume":"193","author":"J Wang","year":"2021","unstructured":"Wang J, Zhang R, Wu X, Li F, Yang H, Liu L, et al. Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory\/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial. Br J Haematol. 2021;193:761\u20138.","journal-title":"Br J Haematol"},{"key":"2582_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-024-01167-8","volume":"14","author":"GG Fortuna","year":"2024","unstructured":"Fortuna GG, Banerjee R, Savid-Frontera C, Song J, Mor\u00e1n-Segura CM, Nguyen JV, et al. Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma. Blood Cancer J. 2024;14:1\u20138.","journal-title":"Blood Cancer J"},{"key":"2582_CR43","unstructured":"ONS 2024: Incidence and Management of Cranial Nerve Impairments in Patients With Multiple Myeloma Treated With Ciltacabtagene Autoleucel in CARTITUDE Studies [Internet]. [cited 2025 Jan 22]. Available from: https:\/\/clin.larvol.com\/abstract-detail\/ONS%202024\/70145524"},{"key":"2582_CR44","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1182\/blood.2023020571","volume":"142","author":"P Karschnia","year":"2023","unstructured":"Karschnia P, Miller KC, Yee AJ, Rejeski K, Johnson PC, Raje N, et al. Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells. Blood. 2023;142:1243\u20138.","journal-title":"Blood"},{"key":"2582_CR45","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","volume":"27","author":"O Van Oekelen","year":"2021","unstructured":"Van Oekelen O, Aleman A, Upadhyaya B, Schnakenberg S, Madduri D, Gavane S, et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat Med. 2021;27:2099\u2013103.","journal-title":"Nat Med"},{"key":"2582_CR46","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1182\/bloodadvances.2023012470","volume":"8","author":"M Mejia Saldarriaga","year":"2024","unstructured":"Mejia Saldarriaga M, Pan D, Unkenholz C, Mouhieddine TH, Velez-Hernandez JE, Engles K, et al. Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma. Blood Adv. 2024;8:3859\u201369.","journal-title":"Blood Adv"},{"key":"2582_CR47","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood.2023020578","volume":"142","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi A, Barba P, et al. Immune effector cell\u2013associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations. Blood. 2023;142:865\u201377.","journal-title":"Blood"},{"key":"2582_CR48","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1182\/blood.2020010543","volume":"138","author":"K Rejeski","year":"2021","unstructured":"Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, et al. CAR-HEMATOTOX: a model for CAR T-cell\u2013related hematologic toxicity in relapsed\/refractory large B-cell lymphoma. Blood. 2021;138:2499\u2013513.","journal-title":"Blood"},{"key":"2582_CR49","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","volume":"16","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Hansen DK, Bansal R, Sesques P, Ailawadhi S, Logue JM, et al. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma. J Hematol Oncol. 2023;16:88.","journal-title":"J Hematol Oncol"},{"key":"2582_CR50","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jtct.2023.05.012","volume":"29","author":"JA Davis","year":"2023","unstructured":"Davis JA, Sborov DW, Wesson W, Julian K, Abdallah AO, McGuirk JP, et al. Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy. Transplant Cell Ther. 2023;29:567\u201371.","journal-title":"Transplant Cell Ther"},{"key":"2582_CR51","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jaip.2021.10.037","volume":"10","author":"J Wat","year":"2022","unstructured":"Wat J, Barmettler S. Hypogammaglobulinemia after Chimeric Antigen Receptor (CAR) T-cell therapy: characteristics, management, and future directions. J Allergy Clin Immunol Pr. 2022;10:460\u20136.","journal-title":"J Allergy Clin Immunol Pr"},{"key":"2582_CR52","doi-asserted-by":"publisher","first-page":"5290","DOI":"10.1182\/bloodadvances.2021004603","volume":"5","author":"Y Wang","year":"2021","unstructured":"Wang Y, Li C, Xia J, Li P, Cao J, Pan B, et al. Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma. Blood Adv. 2021;5:5290\u20139.","journal-title":"Blood Adv"},{"key":"2582_CR53","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","volume":"4","author":"G Lancman","year":"2023","unstructured":"Lancman G, Parsa K, Kotlarz K, Avery L, Lurie A, Lieberman-Cribbin A, et al. IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies. Blood Cancer Discov. 2023;4:440\u201351.","journal-title":"Blood Cancer Discov"},{"key":"2582_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-023-00886-8","volume":"13","author":"CJ Ferreri","year":"2023","unstructured":"Ferreri CJ, Hildebrandt MAT, Hashmi H, Shune LO, McGuirk JP, Sborov DW, et al. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 2023;13:1\u20139.","journal-title":"Blood Cancer J"},{"key":"2582_CR55","unstructured":"Charting the Course: Sequencing Immunotherapy for Multiple Myeloma | American Society of Clinical Oncology Educational Book [Internet]. [cited 2024 Jul 14]. Available from: https:\/\/ascopubs.org\/doi\/10.1200\/EDBK_432204"},{"key":"2582_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21177-5","volume":"12","author":"MK Samur","year":"2021","unstructured":"Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai YT, Prabhala R, et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021;12:868.","journal-title":"Nat Commun"},{"key":"2582_CR57","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40164-023-00402-5","volume":"12","author":"W Li","year":"2023","unstructured":"Li W, Zhang B, Cao W, Zhang W, Li T, Liu L, et al. Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed\/refractory multiple myeloma through single-cell sequencing. Exp Hematol Oncol. 2023;12:44.","journal-title":"Exp Hematol Oncol"},{"key":"2582_CR58","doi-asserted-by":"publisher","first-page":"e20049","DOI":"10.1200\/JCO.2023.41.16_suppl.e20049","volume":"41","author":"U Patel","year":"2023","unstructured":"Patel U, Oluwole OO, Kassim A, Jayani R, Belliveau P, Savani B, et al. Sequencing bispecific antibodies and CAR T cell therapy in multiple myeloma with prior exposure to BCMA-targeted therapies. JCO. 2023;41:e20049\u2013e20049.","journal-title":"JCO"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02582-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02582-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02582-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T04:02:40Z","timestamp":1751860960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02582-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":58,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2582"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02582-6","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"assertion":[{"value":"22 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}